Wells Fargo upgraded Monte Rosa Therapeutics (GLUE) to Overweight from Equal Weight with a $22 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics presents preclinical data on MRT-8102
- Monte Rosa Therapeutics Reports Strong Revenue Growth
- Monte Rosa Therapeutics: Promising Advancements and Financial Stability Drive Buy Rating
- Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating
- Monte Rosa Announces Q3 Results and Novartis Collaboration